NVE Schedules Conference Call on Second-Quarter Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
NVE Schedules Conference Call on Second-Quarter Results

EDEN PRAIRIE, Minn., Oct. 10, 2016 (GLOBE NEWSWIRE) -- NVE Corporation (Nasdaq: NVEC) announced that it plans to release its financial results for the quarter ended September 30, 2016 on Wednesday, October 19, 2016 after the close of the Nasdaq Regular Market. The company will hold its quarterly conference call later that day at 4:00 p.m. Central Time. The quarterly call will be broadcast live over the Internet and can be accessed through the Investor Events page of NVE’s Website ( www.nve.com ). An archive of the call will also be available. Parties who wish to participate in the call are requested to contact NVE Investor Relations at 952-829-9217 no later than October 17, 2016 to reserve a position for the call and to receive the conference telephone number. NVE is a leader in the practical commercialization of spintronics, a nanotechnology that relies on electron spin rather than electron charge to acquire, store and transmit information. The company manufactures high-performance spintronic products including sensors and couplers that are used to acquire and transmit data. NVE has also licensed its spintronic magnetoresistive random access memory technology, commonly known as MRAM. Statements we use that relate to future plans, events, financial results or performance are forward-looking statements that are subject to certain risks and uncertainties including, among others, the risk factors listed from time to time in our filings with the SEC, including our Annual Report on Form 10-K and other reports filed with the SEC.

Curt Reynders 952-829-9217

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Insights from the New First Presidency on Global Challenges

Updated Category News Views 218

A Historic Conversation with the First Presidency The recent interview featuring the new First Presidency of The Church of Jesus Christ of Latter-day Saints marks an exciting milestone. Conducted by the talented Jane Clayson Johnson, this unique dialogue sheds light on pressing issues within the Church and broader society. It was their first public discussion, making it a...

Continue Reading
Major Bets on Donald Trump's Election Surge Past $52 Million

Updated Category News Views 119

Significant Bets on Trump's Electoral Success A trader on Polymarket, operating under the alias Fredi9999, alongside four other accounts, has made headlines recently by placing enormous bets on Donald Trump’s electoral prospects. This activity has generated considerable chatter among traders in the market. Tracking Trump's Betting Activity Harry Crane, a statistics...

Continue Reading
FMC Corporation Faces Lawsuit Over Securities Violations

Updated Category News Views 190

FMC Corporation Faces Lawsuit Over Securities Violations Recently, the Gross Law Firm has alerted shareholders of FMC Corporation (NYSE: FMC) regarding significant legal developments. This lawsuit brings attention to serious allegations concerning the company's conduct during a specific class period. Shareholder Engagement and Participation Shareholders who purchased FMC...

Continue Reading
Insider Buying at Optima Health Signals Confidence in Future Growth

Updated Category News Views 132

Insightful Insider Share Purchase at Optima Health Optima Health plc (AIM: OPT), a leading provider of corporate health and wellbeing solutions in the UK, recently announced an important transaction involving one of its key insiders. Joanne Newey, who takes on the role of Group Business Development & Propositions Director and is also a Person Discharging Managerial...

Continue Reading
Outlook Therapeutics Prepares for Upcoming Investor Interaction

Updated Category News Views 78

Outlook Therapeutics Connects with Investors at Upcoming Virtual Event ISELIN, N.J. — Outlook Therapeutics, Inc. (Nasdaq: OTLK) has been making waves in the biopharmaceutical field with its groundbreaking ocular therapy. This marks an exciting era for the company following the recent approval of its eye treatment formulation of bevacizumab, which targets wet age-related...

Continue Reading